Keywords
SARS-CoV-2
group I pathogens
pathogen classification
lethality
vaccines
treatment methods
public health
pandemic
Abstract
COVID-19, caused by SARS-CoV-2 virus, has had a great impact on the world economy and health care system of different countries, but the categorization as pathogenicity group I needs revision. This group includes viruses that cause particularly dangerous diseases in humans and animals, such pathogens have a high level of virulence, cause massive outbreaks of disease, and have high lethality. All types of work with viruses of the I group of pathogenicity and microorganisms, the taxonomic position of which is not determined, and the degree of danger is not studied, as well as aerobiological studies are carried out in maximum isolated laboratories. Also, an important factor of categorization to the I group is the absence of effective methods of treatment of the caused disease. Examples of representatives of this group of viruses are Ebola and Marburg viruses, the mortality rate of which reaches 90 %. Analysis of statistical data on COVID-19 morbidity indicates that its characteristics largely do not meet the basic criteria for classification as the I group of pathogenicity. The lethality rate of COVID-19 is significantly lower than that of other representatives (not exceeding 2 %). Also, the existence of registered and effective methods of treatment against this disease significantly reduces its threat as a viral infection. The conducted statistical analysis of the data indicates that global mortality and morbidity rates do not correspond to the wall of risk characteristic of other representatives of the I group. Therefore, COVID-19 should be reclassified to better reflect its characteristics in order to optimize the countermeasure strategy and more standardized responses.
For citation
Emelyanov VN, Virko VA, Besedin AD, Andreevsky GV. COVID‑19 and its inconsistency with the characteristics of pathogens of the I pathogenicity group: Comparative analysis. USMU Medical Bulletin. 2024;(3):17–24. (In Russ.). EDN: https://elibrary.ru/PUALDL.
References
Gatherer D. The 2014 Ebola Virus Disease Outbreak in West Africa // Journal of General Virology. 2014. Vol. 95, Iss. 8. P. 1619–1624. DOI: https://doi.org/10.1099/vir.0.067199-0.
Pathogenicity and Virulence of Marburg Virus / M. H. Abir, T. Rahman, A. Das [et al.] // Virulence. 2022. Vol. 13, Iss. 1. P. 609–633. DOI: https://doi.org/10.1080/21505594.2022.2054760.
Ohimain E. I., Silas-Olu D. The 2013–2016 Ebola Virus Disease Outbreak in West Africa // Current Opinion in Pharmacology. 2021. Vol. 60. P. 360–365. DOI: https://doi.org/10.1016/j.coph.2021.08.002.
Sahoo S., Narang R. K., Singh A. The Marburg Virus Outbreak in West Africa // Current Drug Targets. 2023. Vol. 24, Iss. 5. P. 380–381. DOI: http://dx.doi.org/10.2174/1389450124666230213154319.
Characteristics of SARS-CoV‑2 and COVID‑19 / B. Hu, H. Guo, P. Zhou, Z. L. Shi // Nature Reviews Microbiology. 2021. Vol. 19, Iss. 3. P. 141–154. DOI: https://doi.org/10.1038/s41579-020-00459-7. Erratum in: Nature Reviews Microbiology. 2022. Vol. 20, Iss. 5. P. 315. DOI: https://doi.org/10.1038/s41579-022-00711-2.
Рудаков Н. В., Пеньевская Н. А. Федеральный проект «Санитарный щит страны — безопасность для здоровья (предупреждение, выявление, реагирование)» — важнейший этап реализации стратегии национальной безопасности Российской Федерации // Национальные приоритеты России. 2024. № 2. С. 47–59. EDN: https://elibrary.ru/beaecf.
Смирнов А. Ю. Анализ смертности от коронавирусной инфекции в России // Народонаселение. 2021. Т. 24, № 2. С. 76–86. DOI: https://doi.org/10.19181/population.2021.24.2.7.
Review and Classification of AI-Enabled COVID‑19 CT Imaging Models Based on Computer Vision Tasks / H. Hassan, Z. Ren, H. Zhao [et al.] // Computers in Biology and Medicine. 2022. Vol. 141, Art. No. 105123. DOI: https://doi.org/10.1016/j.compbiomed.2021.105123.
Mousavizadeh L., Ghasemi S. Genotype and Phenotype of COVID‑19: Their Roles in Pathogenesis // Journal of Microbiology, Immunology and Infection. 2021. Vol. 54, Iss. 2. P. 159–163. DOI: https://doi.org/10.1016/j.jmii.2020.03.022.
Progress of the COVID‑19 Vaccine Effort: Viruses, Vaccines and Variants Versus Efficacy, Effectiveness and Escape / J. S. Tregoning, K. E. Flight, S. L. Higham [et al.] // Nature Reviews Immunology. 2021. Vol. 21, Iss. 10. P. 626–636. DOI: https://doi.org/10.1038/s41577-021-00592-1.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
Copyright © 2024 Emelyanov V. N., Virko V. A., Besedin A. D., Andreevsky G. V.